Therapeutic compositions and methods for treating cancers
The present disclosure provides therapeutic combinations, which provide a synergistic effect in treating a cancer. The present disclosure provides methods of treatment including administration of the combinations, and uses of the combinations, e.g., for treatment of cancer.
1 . A pharmaceutical composition comprising a therapeutically effective amount of idelalisib and a therapeutically effective amount of defactinib, wherein the amounts are synergistically effective to treat triple negative breast cancer.
2 . The pharmaceutical composition of claim 1 , wherein the synergistically effective amounts provide for:
more than an additive effect of the combination compared to their individual effects; and/or
administration of at least one of the agents at a lower dosage than the dose of that agent that would be required to achieve the same therapeutic effect when the agent is administered as a monotherapy.
3 . The pharmaceutical composition of claim 1 , wherein the molar ratio of the idelalisib to the defactinib is between 2:1 and 4:1.
4 . A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition of claim 1 , wherein the cancer is triple negative breast cancer.
5 . The method of claim 4 , wherein the triple negative breast cancer is basal-like breast cancer.
6 . The method of claim 4 , wherein the pharmaceutical composition is at least two times more effective at killing malignant cells than it is at killing non-malignant cells.
7 . The method of claim 4 , wherein the pharmaceutical composition is a pharmaceutical combination comprising the idelalisib and the defactinib as separate components of the combination, and wherein the administration of the idelalisib component and the defactinib component is simultaneous.
8 . The method of claim 4 , wherein the pharmaceutical composition is a pharmaceutical combination comprising the idelalisib and the defactinib as separate components of the combination, and wherein the administration of the idelalisib component and the defactinib component is sequential.